On April 10, the signing ceremony and work promotion meeting of The Framework Agreement on Equity Acquisition Cooperation between Lijun Pharma and Shaanxi Defukang Pharma were successfully held in Xi'an headquarters.

 Representatives of both parties jointly signed the equity acquisition cooperation framework agreement,  The signing ceremony was hosted by Wu Yuanyuan, Director of Lijun Health Pharmaceutical Group and Director of Lijun Pharma. Wu Qin, The founder of Lijun Brand, Chairman of Joint Investment Group and Chairman of Lijun Enterprise Group. Huang Linyuan, Chairman of Lijun Health Pharmaceutical Group and Vice Chairman of Lijun Pharma. Si Jie, General Manager of Lijun Health Pharmaceutical Group and Director of Lijun Pharma. Liu Zhengdong, General Manager of Defukang Pharma  and other relevant leaders attended the signing ceremony, more than 30 members include Working Group, Production, Sales, Quality, Legal Affairs and Finance attended too.

On the signing ceremony, Chairman Huang Linyuan and General Manager Liu Zhengdong made a speech on behalf of both sides of the equity acquisition; Director Si Jie and General Manager Liu Zhengdong signed the Framework Agreement on Equity Acquisition Cooperation and Shaanxi Defukang Pharma, and director Si Jie arranged and deployed the next work.

Wu Qin,chairman of Lijun Pharma made an important speech at the signing meeting on behalf of the company's decision-makers. He pointed out that Lijun Pharma and Defukang Pharma are both pharmaceutical enterprises with a long history. Based on the fruitful work of the merger and acquisition teams of both sides for more than half a year, today they successfully signed the Framework Agreement on Equity Acquisition Cooperation, which is an important event in the development history of Lijun and Defukang. Lijun Pharma and Defukang Pharma work together to form Lijun Health Pharmaceutical Group, vigorously develop the Chinese medicine sector, layout pharmaceutical raw materials and intermediates, implement drug marketing license holders, and extend Lijun brand resources. It is hoped that the management teams of both sides should adhere to the concept of "unity, inclusiveness, mutual trust" and "resource sharing, complementary advantages" and "adhere to the industry" Based on the principle of "business first, work while improving", strengthen the construction of corporate governance structure and marketing management system of the company, and work hard in the five aspects of traditional Chinese medicine pretreatment, oral liquid of traditional Chinese medicine, distribution of pharmaceutical raw materials, potential tapping of existing products, and creation of advantageous varieties, so as to jointly grow and strengthen the cooperative enterprise and contribute our strength to the development of local pharmaceutical industry inYulin,Shaanxi .

The signing of this Agreement is a strategic layout for Lijun Pharma to focus on future development, combine with Yulin's local resource endowment, extract and build synthetic raw material base before traditional Chinese medicine. After more than half a year's due diligence and comprehensive evaluation, the company's M&A; a team finally completed various negotiations and formally signed the M&A; a cooperation framework agreement.

After the signing of the Agreement, both parties will set up the organizational structure of the new company as soon as possible, establish a national sales network, activate the existing approval number and Lijun traditional Chinese medicine number of Defukang as soon as possible, and strive to build the new company into a new base of traditional Chinese medicine and synthetic raw materials with an annual sales of more than 100 million in 2-3 years.

After signing the Agreement, Liu Zhengdong, General manager of Defukang and his delegation visited the production base of Huyi.

Shaanxi Defukang Pharma was founded in 1969. Its predecessor is the state-owned Yulin Pharmaceutical Factory. In 2002, the enterprise was restructured and changed to Shaanxi Defukang Pharma. in 2010. It is the only pharmaceutical enterprise with a history of 50 years in Yulin. In 2014, the enterprise moved to Mahuanliang industrial park, Yulin city, covering an area of 60 mu. The company mainly engaged in the production of injection, oral liquid, capsule, tablet and other types of Chinese and Western medicine nearly 100 varieties. At present, small volume injection production line, tablet, capsule and granule production line, oral syrup production line and traditional Chinese medicine pre-treatment and extraction production line have been established, which have passed the national GMP certification and put into production.